211 related articles for article (PubMed ID: 28100773)
1. Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.
Kasturirangan S; Rainey GJ; Xu L; Wang X; Portnoff A; Chen T; Fazenbaker C; Zhong H; Bee J; Zeng Z; Jenne C; Wu H; Gao C
J Biol Chem; 2017 Mar; 292(10):4361-4370. PubMed ID: 28100773
[TBL] [Abstract][Full Text] [Related]
2. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.
Chen W; Feng Y; Zhao Q; Zhu Z; Dimitrov DS
Mol Cancer Ther; 2012 Jul; 11(7):1400-10. PubMed ID: 22553356
[TBL] [Abstract][Full Text] [Related]
4. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
5. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.
Leong WS; Thomas KA; Chan CH; Stevenson GT
Mol Immunol; 2011 Feb; 48(5):760-8. PubMed ID: 21196049
[TBL] [Abstract][Full Text] [Related]
6. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver.
Løvdal T; Andersen E; Brech A; Berg T
J Cell Sci; 2000 Sep; 113 ( Pt 18)():3255-66. PubMed ID: 10954423
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
8. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.
Zwolak A; Armstrong AA; Tam SH; Pardinas JR; Goulet DR; Zheng S; Brosnan K; Emmell E; Luo J; Gilliland GL; Chiu ML
MAbs; 2017; 9(8):1306-1316. PubMed ID: 28898162
[TBL] [Abstract][Full Text] [Related]
9. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
11. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.
Iwayanagi Y; Igawa T; Maeda A; Haraya K; Wada NA; Shibahara N; Ohmine K; Nambu T; Nakamura G; Mimoto F; Katada H; Ito S; Tachibana T; Jishage K; Hattori K
J Immunol; 2015 Oct; 195(7):3198-205. PubMed ID: 26320252
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
14. Divergent Requirement of Fc-Fcγ Receptor Interactions for
Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
[TBL] [Abstract][Full Text] [Related]
15. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
17. Harnessing MerTK agonism for targeted therapeutics.
Kedage V; Ellerman D; Chen Y; Liang WC; Borneo J; Wu Y; Yan M
MAbs; 2020; 12(1):1685832. PubMed ID: 31852344
[TBL] [Abstract][Full Text] [Related]
18. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
19. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
[TBL] [Abstract][Full Text] [Related]
20. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
